CMS Update

Analysis completed by Inovalon Division of Research, Development, and Analytics

Christie Teigland, Ph.D., Director Statistical Research (Principal Investigator)

10/20/2014

Submitted by Inovalon on behalf of the Duals Data Collaboration Advisory Panel:

- **Cigna-HealthSpring**—Dr. Paige Huber Reichert, Senior Medical Director of Quality,
- **Wellcare**—Elizabeth Goodman, Vice President of Public Policy and Government Affairs
- **Healthfirst**—Joyce Chan, Assistant Vice President of Clinical Performance
- **Gateway Health**—Dr. Austin Ifedirah, Vice President, Medicare & Strategic Planning
- **BCBS Minnesota & Blue Plus**—Dr. Dave Pautz, Senior Medical Director, Government Programs
- **Health Care Services Corporation (HCSC)**--Susan Sommers, Divisional Vice President, Medicaid Programs
- **SNP Alliance**—Richard Bringewatt, President, National Health Policy Group and President
- **Medicaid Health Plans of America (MHPA)**—Jeffrey M Myers, President and CEO

Random Effect Models (2013 data)

Model 1: Measure = Member Dual Status With Random Effect of PBP

Sample	Measure	Measure Name	Number of PBPs	Number of Members	Member Dual Status (Within Effect)							Random Effect (PBP)	
					Estimate	Stderr	Odds	Lower CI95	Upper CI95	F Value	Probt	ChiSq	GMATRIX pValue
All PBPs	AAP	Adults' Access to Preventive/Ambulatory Health Services	293	1,533,011	0.0717	0.0146	1.0743	1.044	1.1054	24.18	<.0001	18859.2	<.0001
	AMM	Antidepressant Medication Management-Effective Continuation Phase Treatment	174	23,194	0.0184	0.038	1.0186	0.9454	1.0974	0.234	0.6295	631.52	<.0001
	ART	Rheumatoid Arthritis Management	171	14,282	-0.1184	0.0581	0.8884	0.7927	0.9956	4.147	0.0439	404.66	<.0001
	BCS	Breast Cancer Screening	272	270,595	-0.2542	0.016	0.7756	0.7516	0.8003	252.253	<.0001	5010.83	<.0001
	BPD	Diabetes Treatment	106	165,399	-0.0123	0.0269	0.9878	0.937	1.0413	0.209	0.6486	1371.78	<.0001
	DDI	Drug-Drug Interactions	204	354,572	-0.2163	0.0218	0.8055	0.7718	0.8407	98.252	<.0001	745.33	<.0001
	HRM	High Risk Medication	216	1,132,327	-0.2865	0.0112	0.7509	0.7346	0.7675	658.499	<.0001	9551.23	<.0001
	IET-E	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Engagement	113	17,437	0.1287	0.1123	1.1374	0.9127	1.4174	1.314	0.2553	399.63	<.0001
	IET-I	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Initiation	113	17,437	0.0136	0.0517	1.0137	0.916	1.1218	0.069	0.7935	2110.48	<.0001
	MA-C	Medication Adherence for Cholesterol (Statins)	203	577,181	-0.0144	0.0096	0.9857	0.9674	1.0043	2.271	0.1337	23300.88	<.0001
	MA-D	Medication Adherence for Diabetes Medications	195	209,077	-0.0032	0.0161	0.9968	0.9658	1.0287	0.041	0.8408	5751.98	<.0001
	MA-H	Medication Adherence for Hypertension (RAS antagonists)	203	610,964	-0.0752	0.0098	0.9275	0.9099	0.9455	59.165	<.0001	18770.16	<.0001
	OMW	Osteoporosis Management in Women who had a Fracture	102	9,964	-0.2684	0.0752	0.7646	0.6599	0.886	12.754	0.0006	1219.74	<.0001
	PBH	Persistence of Beta-Blocker Treatment After a Heart Attack	162	4,998	0.2544	0.1211	1.2897	1.0172	1.6353	4.413	0.0383	55.4	<.0001
	PCE-B	Pharmacotherapy Management of COPD Exacerbation-Bronchodilators	170	11,567	0.4757	0.0673	1.6092	1.4082	1.8388	49.92	<.0001	575.85	<.0001
	PCE-S	Pharmacotherapy Management of COPD Exacerbation-Systemic Corticosteroids	170	11,567	-0.0911	0.0551	0.9129	0.8184	1.0183	2.73	0.1013	249.6	<.0001
	SPR	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	251	31,683	-0.2168	0.0361	0.8051	0.7501	0.8641	36.048	<.0001	678.51	<.0001
	PCR	Plan All-Cause Readmissions											
		0/1, Unadjusted	62	32,563	-0.1598	0.0338	0.852	0.796	0.912	22.31	<.0001	0.25	0.3093
		0/1, Adjusted	62	32,563	-0.079	0.0351	0.924	0.861	0.992	5.06	0.0293	0.89	0.1721
		Expected	62	32,563	-0.0189	0.0015				161.56	<.0001	162.8	<.0001
PBPs with 10 - 90% dual enrollment	AAP	Adults' Access to Preventive/Ambulatory Health Services	112	637,121	0.0595	0.0159	1.0613	1.0287	1.0949	13.992	0.0003	8518.49	<.0001
	AMM	Antidepressant Medication Management-Effective Continuation Phase Treatment	84	9,825	0.0125	0.0457	1.0126	0.9258	1.1076	0.075	0.7849	167.97	<.0001
	ART	Rheumatoid Arthritis Management	87	6,461	-0.0317	0.0712	0.9688	0.8425	1.1139	0.199	0.657	93.69	<.0001
	BCS	Breast Cancer Screening	104	113,659	-0.2058	0.0178	0.814	0.7861	0.843	133.449	<.0001	2696.53	<.0001
	BPD	Diabetes Treatment	42	51,560	0.0008	0.0328	1.0008	0.9384	1.0673	0.001	0.9816	157.91	<.0001
	DDI	Drug-Drug Interactions	90	166,825	-0.2007	0.0258	0.8182	0.7778	0.8607	60.326	<.0001	404.08	<.0001
	HRM	High Risk Medication	93	551,459	-0.277	0.0125	0.758	0.7397	0.7768	492.161	<.0001	5254.52	<.0001
	IET-E	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Engagement	46	8,228	0.1768	0.1228	1.1934	0.9382	1.518	2.074	0.1574	224.65	<.0001
	IET-I	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Initiation	46	8,228	0.0651	0.0561	1.0673	0.9561	1.1914	1.345	0.2529	1273.09	<.0001
	MA-C	Medication Adherence for Cholesterol (Statins)	92	282,555	-0.0023	0.0104	0.9977	0.9775	1.0183	0.049	0.8252	8946.86	<.0001
	MA-D	Medication Adherence for Diabetes Medications	89	104,988	0.0031	0.0176	1.0031	0.969	1.0384	0.031	0.8599	2738.49	<.0001
	MA-H	Medication Adherence for Hypertension (RAS antagonists)	92	299,486	-0.0571	0.0107	0.9445	0.9249	0.9645	28.47	<.0001	10210.08	<.0001
	OMW	Osteoporosis Management in Women who had a Fracture	42	4,358	-0.2911	0.0897	0.7474	0.627	0.891	10.544	0.0025	746.98	<.0001
	PBH	Persistence of Beta-Blocker Treatment After a Heart Attack	78	2,527	0.3482	0.1572	1.4165	1.0408	1.9277	4.904	0.0304	8.41	0.0019
	PCE-B	Pharmacotherapy Management of COPD Exacerbation-Bronchodilators	84	4,447	0.5191	0.0857	1.6805	1.4169	1.9931	36.73	<.0001	51.04	<.0001
	PCE-S	Pharmacotherapy Management of COPD Exacerbation-Systemic Corticosteroids	84	4,447	-0.138	0.0703	0.8711	0.7574	1.002	3.86	0.0533	13.67	<.0001
	SPR	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	98	14,022	-0.1672	0.0432	0.8461	0.7774	0.9208	-3.8714	0.0002	481.06	<.0001
	PCR	Plan All-Cause Readmissions											
		0/1, Unadjusted	27	11,318	-0.1837	0.0565	0.832	0.741	0.935	10.56	0.0033	n/a	
		0/1, Adjusted	27	11,318	-0.1488	0.0574	0.862	0.766	0.97	6.71	0.0158	n/a	
		Expected	27	11,318	-0.0104	0.0021				25.15	<.0001	49.08	<.0001

Sample	Measure	Measure Name	Number of PBPs	Number of Members	Member Dual Status (Within Effect)							Random Effect (PBP)	
					Estimate	Stderr	Odds	Lower CI95	Upper CI95	F Value	Probt	ChiSq	GMATRIX pValue
PBPs with 20 - 80% dual enrollment	AAP	Adults' Access to Preventive/Ambulatory Health Services	50	274,358	0.1115	0.0202	1.118	1.0747	1.163	30.605	<.0001	3128.06	<.0001
	AMM	Antidepressant Medication Management-Effective Continuation Phase Treatment	45	5,934	0.017	0.0552	1.0172	0.9129	1.1333	0.095	0.759	86.31	<.0001
	ART	Rheumatoid Arthritis Management	43	3,010	0.071	0.0931	1.0736	0.8946	1.2885	0.583	0.4497	59.87	<.0001
	BCS	Breast Cancer Screening	44	50,400	-0.1163	0.024	0.8902	0.8492	0.9332	23.392	<.0001	1178.75	<.0001
	BPD	Diabetes Treatment	23	35,581	-0.0051	0.0374	0.9949	0.9246	1.0705	0.019	0.8929	78.43	<.0001
	DDI	Drug-Drug Interactions	47	74,630	-0.1616	0.0366	0.8508	0.7919	0.914	19.5	<.0001	159.52	<.0001
	HRM	High Risk Medication	48	247,968	-0.2416	0.0172	0.7853	0.7592	0.8123	196.358	<.0001	1721.31	<.0001
	IET-E	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Engagement	27	5,624	0.2008	0.1317	1.2224	0.9443	1.5824	2.324	0.141	156.17	<.0001
	IET-I	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Initiation	27	5,624	0.0187	0.0679	1.0189	0.8919	1.1639	0.076	0.7853	1120.57	<.0001
	MA-C	Medication Adherence for Cholesterol (Statins)	47	132,514	-0.0305	0.0134	0.97	0.9447	0.9958	5.156	0.028	3121.59	<.0001
	MA-D	Medication Adherence for Diabetes Medications	46	52,307	0.043	0.0226	1.044	0.9987	1.0913	3.617	0.0639	1249.51	<.0001
	MA-H	Medication Adherence for Hypertension (RAS antagonists)	47	141,842	-0.0659	0.014	0.9363	0.911	0.9623	22.2	<.0001	4069.06	<.0001
	OMW	Osteoporosis Management in Women who had a Fracture	15	1,327	-0.3354	0.1299	0.715	0.5543	0.9223	6.67	0.0273	190.21	<.0001
	PBH	Persistence of Beta-Blocker Treatment After a Heart Attack	42	1,157	0.2212	0.1896	1.2476	0.8604	1.8089	1.362	0.2509	2.27	0.0657
	PCE-B	Pharmacotherapy Management of COPD Exacerbation-Bronchodilators	44	2,612	0.5439	0.1052	1.7227	1.3918	2.1322	26.6	<.0001	13.52	<.0001
	PCE-S	Pharmacotherapy Management of COPD Exacerbation-Systemic Corticosteroids	44	2,612	-0.166	0.0876	0.847	0.7096	1.0112	3.59	0.0654	3.61	0.0287
	SPR	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	42	6,082	-0.0706	0.0576	0.9318	0.8323	1.0432	1.503	0.2281	383.07	<.0001
	PCR	Plan All-Cause Readmissions											
		0/1, Unadjusted	16	6,660	-0.1649	0.0692	0.848	0.732	0.983	5.67	0.0309	n/a	
		0/1, Adjusted	16	6,660	-0.1422	0.0704	0.867	0.747	1.008	4.08	0.0616	n/a	
		Expected	16	6,660	-0.00717	0.0026				7.85	0.0134	12.75	<.0001

Notes:
Odds ratio less than 1 means that duals perform worse.
Blue color indicates the effect is negative and statistically significant meaning that dual eligibles perform worse than non-dual eligibles;
Green color indicates the effect is positive and statistically significant meaning that dual eligibles perform better than non-dual eligibles.
For reverse measures (HRM, PCR, DDI), the coefficient estimates measure the effect of the variable on NOT having outcome.

Random Effect Models (2013 data)

Model 2: Measure = Member Dual Status + Plan % Dual With Random Effect of PBP
   Dual percentage groups: <10%, 10-<20%, 20-<30%, 30-<90%, 90-100%

Sample	Measure	Measure Name	Number of PBPs	Number of Members	Member Dual Status (Within Effect)							Plan % Dual (Contextual/Between Effect)		Random Effect (PBP)	
					Estimate	Standard Error	Odds	LowerCI	UpperCI	F Value	ProbF	F Value	ProbF	ChiSq	GMATRIX pValue
All PBPs	AAP	Adults' Access to Preventive/Ambulatory Health Services	293	1,533,011	0.0706	0.0146	1.0732	1.0427	1.1046	23.264	<.0001	2.2827	0.0606	17491.59	<.0001
	AMM	Antidepressant Medication Management-Effective Continuation Phase Treatment	174	23,194	0.0753	0.04	1.0782	0.9961	1.1672	3.542	0.0622	8.737	<.0001	456.02	<.0001
	ART	Rheumatoid Arthritis Management	171	14,282	-0.0631	0.065	0.9388	0.8255	1.0678	0.944	0.3333	1.8884	0.1148	373.83	<.0001
	BCS	Breast Cancer Screening	272	270,595	-0.2585	0.0163	0.7722	0.7478	0.7974	251.96	<.0001	0.545	0.7029	4260.48	<.0001
	BPD	Diabetes Treatment	106	165,399	-0.0408	0.0279	0.96	0.9082	1.0148	2.137	0.1472	4.183	0.0036	1186.21	<.0001
	DDI	Drug-Drug Interactions	204	354,572	-0.2288	0.0234	0.795	0.76	0.833	95.95	<.0001	4.36	0.0021	553.99	<.0001
	HRM	High Risk Medication	216	1,132,327	-0.287	0.0112	0.7505	0.7341	0.7673	652.814	<.0001	4.2162	0.0026	7609.51	<.0001
	IET-E	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Engagement	113	17,437	0.0722	0.1176	1.0749	0.8504	1.3587	0.377	0.541	1.8664	0.1216	259.97	<.0001
	IET-I	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Initiation	113	17,437	-0.0008	0.0525	0.9992	0.9	1.1093	0	0.9873	2.1886	0.075	1878.58	<.0001
	MA-C	Medication Adherence for Cholesterol (Statins)	203	577,181	-0.0126	0.0096	0.9875	0.9689	1.0064	1.713	0.1924	1.7577	0.1389	21817.84	<.0001
	MA-D	Medication Adherence for Diabetes Medications	195	209,077	0.0045	0.0164	1.0045	0.9726	1.0375	0.075	0.7843	3.7323	0.006	5552.78	<.0001
	MA-H	Medication Adherence for Hypertension (RAS antagonists)	203	610,964	-0.0713	0.0099	0.9311	0.9132	0.9494	52.342	<.0001	4.6116	0.0014	16723.46	<.0001
	OMW	Osteoporosis Management in Women who had a Fracture	102	9,964	-0.3092	0.0771	0.734	0.6294	0.8561	16.062	0.0001	2.0482	0.0936	1036.11	<.0001
	PBH	Persistence of Beta-Blocker Treatment After a Heart Attack	162	4,998	0.2972	0.1454	1.3461	1.0085	1.7966	4.177	0.0437	0.6976	0.5947	55.06	<.0001
	PCE-B	Pharmacotherapy Management of COPD Exacerbation-Bronchodilators	170	11,567	0.453	0.0729	1.573	1.3614	1.8175	38.59	<.0001	0.43	0.7903	558.41	<.0001
	PCE-S	Pharmacotherapy Management of COPD Exacerbation-Systemic Corticosteroids	170	11,567	-0.0859	0.0617	0.9177	0.812	1.037	1.94	0.1665	0.47	0.7606	238.28	<.0001
	SPR	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	251	31,683	-0.2131	0.0391	0.8081	0.748	0.8729	29.695	<.0001	0.3484	0.845	484.36	<.0001
	PCR	Plan All-Cause Readmissions													
		0/1, Unadjusted	62	32,563	-0.2056	0.04649	0.814	0.741	0.894	19.55	<.0001	1.95	0.1139	0.12	0.3635
		0/1, Adjusted	62	32,563	-0.1253	0.04719	0.882	0.802	0.97	7.05	0.0109	1.86	0.1297	0.2	0.3217
		Expected	62	32,563	-0.0189	0.0016				134.67	<.0001	1.68	0.1682	104.21	<.0001
PBPs with 10 - 90% dual enrollment	AAP	Adults' Access to Preventive/Ambulatory Health Services	112	637,121	0.0606	0.0159	1.0625	1.0295	1.0965	14.508	0.0002	4.5286	0.0129	7781.21	<.0001
	AMM	Antidepressant Medication Management-Effective Continuation Phase Treatment	84	9,825	0.0297	0.046	1.0302	0.9401	1.129	0.419	0.5194	9.1555	0.0003	92.56	<.0001
	ART	Rheumatoid Arthritis Management	87	6,461	-0.0204	0.072	0.9798	0.849	1.1307	0.081	0.7774	1.9752	0.1451	93.35	<.0001
	BCS	Breast Cancer Screening	104	113,659	-0.2062	0.0178	0.8137	0.7853	0.843	133.737	<.0001	0.1494	0.8614	2332.33	<.0001
	BPD	Diabetes Treatment	42	51,560	-0.0056	0.033	0.9945	0.9303	1.063	0.028	0.867	2.3476	0.109	137.3	<.0001
	DDI	Drug-Drug Interactions	90	166,825	-0.2084	0.025	0.812	0.771	0.855	64.63	<.0001	7.71	0.0008	242.07	<.0001
	HRM	High Risk Medication	93	551,459	-0.2787	0.0125	0.7567	0.7382	0.7757	497.906	<.0001	11.3725	<.0001	3552.06	<.0001
	IET-E	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Engagement	46	8,228	0.1665	0.123	1.1812	0.9215	1.5141	1.834	0.1831	2.3457	0.1079	102.59	<.0001
	IET-I	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Initiation	46	8,228	0.0645	0.0562	1.0666	0.9522	1.1948	1.317	0.2578	1.0042	0.3748	1038.73	<.0001
	MA-C	Medication Adherence for Cholesterol (Statins)	92	282,555	-0.0015	0.0104	0.9985	0.978	1.0195	0.02	0.8887	2.7547	0.0691	8712.05	<.0001
	MA-D	Medication Adherence for Diabetes Medications	89	104,988	0.0045	0.0177	1.0046	0.9699	1.0405	0.066	0.7978	1.2259	0.2986	2691.98	<.0001
	MA-H	Medication Adherence for Hypertension (RAS antagonists)	92	299,486	-0.0564	0.0107	0.9451	0.9252	0.9655	27.784	<.0001	1.3458	0.2656	9900.16	<.0001

Sample	Measure	Measure Name	Number of PBPs	Number of Members	Member Dual Status (Within Effect)							Plan % Dual (Contextual/Between Effect)		Random Effect (PBP)	
					Estimate	Standard Error	Odds	LowerCI	UpperCI	F Value	ProbF	F Value	ProbF	ChiSq	GMATRIX pValue
PBPs with 10 - 90% dual enrollment (cont.)	OMW	Osteoporosis Management in Women who had a Fracture	42	4,358	-0.2915	0.0898	0.7471	0.6227	0.8965	10.529	0.0025	0.297	0.7447	676.89	<.0001
	PBH	Persistence of Beta-Blocker Treatment After a Heart Attack	78	2,527	0.3807	0.1606	1.4633	1.0615	2.0171	5.616	0.0209	1.6167	0.2054	7.52	0.003
	PCE-B	Pharmacotherapy Management of COPD Exacerbation-Bronchodilators	84	4,447	0.5139	0.08615	1.6719	1.4082	1.9849	35.58	<.0001	0.33	0.7215	49.29	<.0001
	PCE-S	Pharmacotherapy Management of COPD Exacerbation-Systemic Corticosteroids	84	4,447	-0.1287	0.0708	0.8793	0.7636	1.0125	3.3	0.0732	1.57	0.2137	6.89	0.0043
	SPR	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	98	14,022	-0.166	0.0434	0.847	0.7771	0.9233	14.663	0.0002	0.5766	0.5638	305.13	<.0001
	PCR	Plan All-Cause Readmissions													
		0/1, Unadjusted	27	11,318	-0.1811	0.0578	0.834	0.741	0.94	9.81	0.0044	2.42	0.1101	n/a*	
		0/1, Adjusted	27	11,318	-0.1449	0.0587	0.865	0.767	0.976	6.1	0.0207	2.49	0.1042	n/a*	
		Expected	27	11,318	-0.0104	0.0021				25.04	<.0001	0	0.9981	51.69	<.0001
PBPs with 20 - 80% dual enrollment	AAP	Adults' Access to Preventive/Ambulatory Health Services	50	274,358	0.1129	0.0202	1.1195	1.075	1.1658	31.338	<.0001	13.2194	0.0007	2738.77	<.0001
	AMM	Antidepressant Medication Management-Effective Continuation Phase Treatment	45	5,934	0.0291	0.0553	1.0295	0.9207	1.1512	0.277	0.6019	13.0109	0.0008	56.64	<.0001
	ART	Rheumatoid Arthritis Management	43	3,010	0.0671	0.0938	1.0694	0.8849	1.2924	0.512	0.4782	0.0992	0.7544	61.33	<.0001
	BCS	Breast Cancer Screening	44	50,400	-0.1165	0.0241	0.8901	0.8478	0.9345	23.419	<.0001	0.0186	0.8921	1116.06	<.0001
	BPD	Diabetes Treatment	23	35,581	-0.0091	0.0374	0.9909	0.9169	1.071	0.059	0.8103	4.1027	0.0557	63.04	<.0001
	DDI	Drug-Drug Interactions	47	74,630	-0.1689	0.0367	0.845	0.784	0.909	21.16	<.0001	7.39	0.0093	111.79	<.0001
	HRM	High Risk Medication	48	247,968	-0.2436	0.0172	0.7838	0.757	0.8115	199.51	<.0001	27.3384	<.0001	1275.59	<.0001
	IET-E	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Engagement	27	5,624	0.2031	0.1318	1.2252	0.9329	1.6091	2.376	0.1369	0.3912	0.5373	99.46	<.0001
	IET-I	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Initiation	27	5,624	0.0193	0.0679	1.0195	0.8859	1.1733	0.081	0.7787	0.345	0.5622	971.21	<.0001
	MA-C	Medication Adherence for Cholesterol (Statins)	47	132,514	-0.0294	0.0134	0.971	0.945	0.9976	4.799	0.0337	6.371	0.0152	3128.84	<.0001
	MA-D	Medication Adherence for Diabetes Medications	46	52,307	0.0444	0.0226	1.0454	0.9987	1.0942	3.842	0.0565	1.6623	0.204	1254.57	<.0001
	MA-H	Medication Adherence for Hypertension (RAS antagonists)	47	141,842	-0.0653	0.014	0.9368	0.9108	0.9636	21.8	<.0001	1.8359	0.1822	4076.09	<.0001
	OMW	Osteoporosis Management in Women who had a Fracture	15	1,327	-0.3333	0.1302	0.7166	0.5362	0.9577	6.556	0.0283	0.2973	0.5948	143.99	<.0001
	PBH	Persistence of Beta-Blocker Treatment After a Heart Attack	42	1,157	0.1945	0.1935	1.2147	0.8205	1.7984	1.011	0.3214	0.3984	0.5315	2.52	0.0562
	PCE-B	Pharmacotherapy Management of COPD Exacerbation-Bronchodilators	44	2,612	0.5347	0.1058	1.707	1.3781	2.1144	25.54	<.0001	0.9	0.3472	12.03	0.0003
	PCE-S	Pharmacotherapy Management of COPD Exacerbation-Systemic Corticosteroids	44	2,612	-0.1522	0.0867	0.8588	0.7206	1.0236	3.08	0.0872	7.46	0.0092	0.04	0.4182
	SPR	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	42	6,082	-0.0717	0.0577	0.9309	0.8281	1.0464	1.543	0.2223	0.1063	0.746	243.72	<.0001
	PCR	Plan All-Cause Readmissions													
		0/1, Unadjusted	16	6,660	-0.1825	0.0702	0.833	0.717	0.968	6.76	0.0201	2.49	0.1371	n/a	
		0/1, Adjusted	16	6,660	-0.1594	0.0713	0.853	0.732	0.993	5	0.041	2.43	0.141	n/a	
		Expected	16	6,660	-0.0072	0.0026				7.81	0.0136	0	0.9611	18.71	<.0001

Notes:

Odds ratio less than 1 means that duals perform worse.

Blue color indicates the effect is negative and statistically significant meaning that dual eligibles perform worse than non-dual eligibles;

Green color indicates the effect is positive and statistically significant meaning that dual eligibles perform better than non-dual eligibles.

For reverse measures (HRM, PCR, DDI), the coefficient estimates measure the effect of the variable on NOT having outcome.

Random Effect Models (2013 data)

Model 3: Identifies Contextual Effect of Plan % Dual on Member Outcomes With Random Effect of PBP

Sample	Measure	Measure Name	Number of PBPs	Number of Members	Member Dual Status (Deviation, Within Effect)		Plan % Dual (Between Effect)		Contextual Effect (Between - Within)			
					Estimate	P-value	Estimate	P-value	Estimate	Standard Error	T Value	P-value
All PBPs	AAP	Adults' Access to Preventive/Ambulatory Health Services	293	1,533,011	0.071	<.0001	0.1649	0.2615	0.0942	0.1474	0.6390	0.5228
	AMM	Antidepressant Medication Management-Effective Continuation Phase Treatment	174	23,194	0.076	0.0581	-0.4942	<.0001	-0.5701	0.1148	-4.9660	<.0001
	ART	Rheumatoid Arthritis Management	171	14,282	-0.064	0.3294	-0.3445	0.0088	-0.2809	0.1456	-1.929	0.0537
	BCS	Breast Cancer Screening	272	270,595	-0.258	<.0001	-0.1396	0.1035	0.1187	0.0871	1.3633	0.1728
	BPD	Diabetes Treatment	106	165,399	-0.041	0.1384	0.3184	0.0006	0.3598	0.0942	3.8205	0.0001
	DDI	Drug-Drug Interactions	204	354,572	-0.229	<.0001	-0.1312	0.0269	0.0982	0.0632	1.5536	0.1203
	HRM	High Risk Medication	216	1,132,327	-0.287	<.0001	-0.2459	0.0187	0.0411	0.1044	0.3937	0.6938
	IET-E	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Engagement	113	17,437	0.084	0.4754	0.5762	0.1115	0.4921	0.3749	1.3125	0.1894
	IET-I	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Initiation	113	17,437	0.005	0.9270	0.2858	0.3173	0.2810	0.2887	0.9733	0.3304
	MA-C	Medication Adherence for Cholesterol (Statins)	203	577,181	-0.013	0.1922	-0.1680	0.0554	-0.1554	0.0877	-1.7718	0.0764
	MA-D	Medication Adherence for Diabetes Medications	195	209,077	0.005	0.7793	-0.2493	0.0063	-0.2539	0.0918	-2.7653	0.0057
	MA-H	Medication Adherence for Hypertension (RAS antagonists)	203	610,964	-0.071	<.0001	-0.3168	<.0001	-0.2455	0.0761	-3.2259	0.0013
	OMW	Osteoporosis Management in Women who had a Fracture	102	9,964	-0.312	<.0001	0.6692	0.0503	0.9814	0.3462	2.8348	0.0046
	PBH	Persistence of Beta-Blocker Treatment After a Heart Attack	162	4,998	0.298	0.0422	0.1543	0.4889	-0.1437	0.2680	-0.5362	0.5918
	PCE-B	Pharmacotherapy Management of COPD Exacerbation-Bronchodilators	170	11,567	0.444	<.0001	0.6119	0.0002	0.1681	0.1759	0.9557	0.3393
	PCE-S	Pharmacotherapy Management of COPD Exacerbation-Systemic Corticosteroids	170	11,567	-0.087	0.1571	-0.0980	0.3820	-0.0107	0.1253	-0.0852	0.9321
	SPR	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	251	31,683	-0.216	<.0001	-0.2203	0.0185	-0.0041	0.1008	-0.0407	0.9676
	PCR	Plan All-Cause Readmissions										
		0/1, Unadjusted	62	32,563	-0.210	<.0001	-0.1090	0.0233	0.1007	0.0655	1.5383	0.1240
		0/1, Adjusted	62	32,563	-0.129	0.0067	-0.0230	0.6449	0.1058	0.0676	1.5650	0.1176
		Expected	62	32,563	-0.019	<.0001	-0.0185	<.0001	0.0004	0.0040	0.1103	0.9121
PBPs with 10-90% Dual Enrollment	AAP	Adults' Access to Preventive/Ambulatory Health Services	112	637,121	0.061	0.0001	-1.2344	0.0197	-1.2950	0.5217	-2.482	0.0131
	AMM	Antidepressant Medication Management-Effective Continuation Phase Treatment	84	9,825	0.030	0.5091	-1.3496	0.0005	-1.3800	0.3731	-3.699	0.0002
	ART	Rheumatoid Arthritis Management	87	6,461	-0.022	0.7592	-0.4052	0.3911	-0.3831	0.4766	-0.804	0.4216
	BCS	Breast Cancer Screening	104	113,659	-0.207	<.0001	0.0402	0.9082	0.2467	0.3482	0.709	0.4786
	BPD	Diabetes Treatment	42	51,560	-0.008	0.8098	0.6612	0.0213	0.6692	0.2778	2.409	0.0160
	DDI	Drug-Drug Interactions	90	166,825	-0.209	<.0001	0.6229	0.0088	0.8319	0.2341	3.554	0.0004
	HRM	High Risk Medication	93	551,459	-0.279	<.0001	0.9455	0.0032	1.2243	0.3125	3.918	0.0001
	IET-E	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Engagement	46	8,228	0.174	0.1583	0.6232	0.6562	0.4495	1.3940	0.322	0.7471
	IET-I	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Initiation	46	8,228	0.067	0.2333	-0.7794	0.4884	-0.8464	1.1165	-0.758	0.4484
	MA-C	Medication Adherence for Cholesterol (Statins)	92	282,555	-0.001	0.8924	-0.4918	0.0463	-0.4904	0.2436	-2.013	0.0441
	MA-D	Medication Adherence for Diabetes Medications	89	104,988	0.004	0.8118	-0.2845	0.3211	-0.2887	0.2856	-1.011	0.3121

Sample	Measure	Measure Name	Number of PBPs	Number of Members	Member Dual Status (Deviation, Within Effect)		Plan % Dual (Between Effect)		Contextual Effect (Between - Within)			
					Estimate	P-value	Estimate	P-value	Estimate	Standard Error	T Value	P-value
PBPs with 10-90% Dual Enrollment (cont.)	MA-H	Medication Adherence for Hypertension (RAS antagonists)	92	299,486	-0.057	<.0001	-0.3654	0.1492	-0.3089	0.2514	-1.229	0.2192
	OMW	Osteoporosis Management in Women who had a Fracture	42	4,358	-0.295	0.0010	0.5720	0.6597	0.8671	1.2921	0.671	0.5022
	PBH	Persistence of Beta-Blocker Treatment After a Heart Attack	78	2,527	0.367	0.0233	0.0112	0.9868	-0.3558	0.6930	-0.513	0.6077
	PCE-B	Pharmacotherapy Management of COPD Exacerbation-Bronchodilators	84	4,447	0.503	<.0001	1.0377	0.0690	0.5349	0.5685	0.941	0.3468
	PCE-S	Pharmacotherapy Management of COPD Exacerbation-Systemic Corticosteroids	84	4,447	-0.125	0.0792	-0.5025	0.1990	-0.3776	0.3943	-0.958	0.3383
	SPR	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	98	14,022	-0.168	0.0001	-0.0744	0.8449	0.0940	0.3815	0.246	0.8054
	PCR	Plan All-Cause Readmissions										
		0/1, Unadjusted	27	11,318	-0.186	0.0014	-0.1247	0.6116	0.0613	0.2496	0.246	0.8060
		0/1, Adjusted	27	11,318	-0.149	0.0115	-0.1069	0.6734	0.0425	0.2573	0.165	0.8688
		Expected	27	11,318	-0.011	<.0001	0.0000	0.9983	0.0105	0.0173	0.607	0.5436
PBPs with 20-80% Dual Enrollment												
	AAP	Adults' Access to Preventive/Ambulatory Health Services	50	274,358	0.113	<.0001	-1.7825	0.0102	-1.896	0.6664	-2.844	0.0045
	AMM	Antidepressant Medication Management-Effective Continuation Phase Treatment	45	5,934	0.030	0.5878	-1.7310	0.0038	-1.761	0.5676	-3.103	0.0019
	ART	Rheumatoid Arthritis Management	43	3,010	0.064	0.4957	0.4388	0.5760	0.375	0.7865	0.476	0.6338
	BCS	Breast Cancer Screening	44	50,400	-0.118	<.0001	0.4566	0.4037	0.574	0.5420	1.059	0.2894
	BPD	Diabetes Treatment	23	35,581	-0.012	0.7541	0.7251	0.0674	0.737	0.3781	1.949	0.0513
	DDI	Drug-Drug Interactions	47	74,630	-0.172	<.0001	0.7081	0.0372	0.880	0.3320	2.649	0.0081
	HRM	High Risk Medication	48	247,968	-0.244	<.0001	1.4597	0.0010	1.704	0.4141	4.114	0.0000
	IET-E	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Engagement	27	5,624	0.204	0.1225	-0.8094	0.7052	-1.013	2.1168	-0.479	0.6323
	IET-I	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Initiation	27	5,624	0.020	0.7676	-1.6732	0.4065	-1.693	1.9821	-0.854	0.3930
	MA-C	Medication Adherence for Cholesterol (Statins)	47	132,514	-0.029	0.0297	-0.7378	0.0251	-0.709	0.3188	-2.223	0.0262
	MA-D	Medication Adherence for Diabetes Medications	46	52,307	0.044	0.0527	-0.2083	0.6001	-0.252	0.3953	-0.638	0.5234
	MA-H	Medication Adherence for Hypertension (RAS antagonists)	47	141,842	-0.065	<.0001	-0.3903	0.3028	-0.325	0.3747	-0.867	0.3859
	OMW	Osteoporosis Management in Women who had a Fracture	15	1,327	-0.337	0.0098	-0.1324	0.9506	0.204	2.0993	0.097	0.9225
	PBH	Persistence of Beta-Blocker Treatment After a Heart Attack	42	1,157	0.160	0.4108	1.4286	0.0886	1.269	0.8435	1.504	0.1329
	PCE-B	Pharmacotherapy Management of COPD Exacerbation-Bronchodilators	44	2,612	0.521	<.0001	1.4787	0.0464	0.958	0.7274	1.317	0.1880
	PCE-S	Pharmacotherapy Management of COPD Exacerbation-Systemic Corticosteroids	44	2,612	-0.141	0.1103	-0.9422	0.0583	-0.801	0.4918	-1.629	0.1035
	SPR	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	42	6,082	-0.074	0.1995	0.5312	0.4645	0.605	0.7214	0.839	0.4014
	PCR	Plan All-Cause Readmissions										
		0/1, Unadjusted	16	6,660	-0.193	0.0065	0.4789	0.2078	0.672	0.3713	1.810	0.0704
		0/1, Adjusted	16	6,660	-0.171	0.0178	0.5432	0.1666	0.714	0.3806	1.876	0.0607
		Expected	16	6,660	-0.007	0.0044	0.0060	0.8106	0.013	0.0248	0.539	0.5901

Notes:

Blue color indicates the effect is negative and statistically significant meaning that dual eligibles perform worse than non-dual eligibles;

Green color indicates the effect is positive and statistically significant meaning that dual eligibles perform better than non-dual eligibles.

For reverse measures (HRM, PCR, DDI), the coefficient estimates measure the effect of the variable on NOT having outcome.

Random Effect Models (2013 data)

Comparison of Member Dual Status (Within Effect) Across Three Models

Sample	Measure	Measure Name	Number of PBPs	Model 1 Dual status (Within)		Model 2 Dual status (Within)		Model 3 Dual Status (Deviation)	
				Estimate	P Value	Estimate	P Value	Estimate	P Value
All PBPs	AAP	Adults' Access to Preventive/Ambulatory Health Services	293	0.0717	<.0001	0.0706	<.0001	0.071	<.0001
	AMM	Antidepressant Medication Management-Effective Continuation Phase Treatment	174	0.0184	0.6295	0.0753	0.0622	0.076	0.0581
	ART	Rheumatoid Arthritis Management	171	-0.1184	0.0439	-0.0631	0.3333	-0.064	0.3294
	BCS	Breast Cancer Screening	272	-0.2542	<.0001	-0.2585	<.0001	-0.258	<.0001
	BPD	Diabetes Treatment	106	-0.0123	0.6486	-0.0408	0.1472	-0.041	0.1384
	DDI	Drug-Drug Interactions	204	-0.2163	<.0001	-0.2288	<.0001	-0.229	<.0001
	HRM	High Risk Medication	216	-0.2865	<.0001	-0.287	<.0001	-0.287	<.0001
	IET-E	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Engagement	113	0.1287	0.2553	0.0722	0.541	0.084	0.4754
	IET-I	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Initiation	113	0.0136	0.7935	-0.0008	0.9873	0.005	0.9270
	MA-C	Medication Adherence for Cholesterol (Statins)	203	-0.0144	0.1337	-0.0126	0.1924	-0.013	0.1922
	MA-D	Medication Adherence for Diabetes Medications	195	-0.0032	0.8408	0.0045	0.7843	0.005	0.7793
	MA-H	Medication Adherence for Hypertension (RAS antagonists)	203	-0.0752	<.0001	-0.0713	<.0001	-0.071	<.0001
	OMW	Osteoporosis Management in Women who had a Fracture	102	-0.2684	0.0006	-0.3092	0.0001	-0.312	<.0001
	PBH	Persistence of Beta-Blocker Treatment After a Heart Attack	162	0.2544	0.0383	0.2972	0.0437	0.298	0.0422
	PCE-B	Pharmacotherapy Management of COPD Exacerbation-Bronchodilators	170	0.4757	<.0001	0.453	<.0001	0.444	<.0001
	PCE-S	Pharmacotherapy Management of COPD Exacerbation-Systemic Corticosteroids	170	-0.0911	0.1013	-0.0859	0.1665	-0.087	0.1571
	SPR	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	251	-0.2168	<.0001	-0.2131	<.0001	-0.216	<.0001
	PCR	Plan All-Cause Readmissions							
		0/1, Unadjusted	62	-0.1598	<.0001	-0.2056	<.0001	-0.210	<.0001
		0/1, Adjusted	62	-0.079	0.0293	-0.1253	0.0109	-0.129	0.0067
		Expected	62	-0.0189	<.0001	-0.0189	<.0001	-0.019	<.0001

Sample	Measure	Measure Name	Number of PBPs	Model 1 Dual status (Within)		Model 2 Dual status (Within)		Model 3 Dual Status (Deviation)	
				Estimate	P Value	Estimate	P Value	Estimate	P Value
PBPs with 10 - 90% dual enrollment									
	AAP	Adults' Access to Preventive/Ambulatory Health Services	112	0.0595	0.0003	0.0606	0.0002	0.061	0.0001
	AMM	Antidepressant Medication Management-Effective Continuation Phase Treatment	84	0.0125	0.7849	0.0297	0.5194	0.030	0.5091
	ART	Rheumatoid Arthritis Management	87	-0.0317	0.657	-0.0204	0.7774	-0.022	0.7592
	BCS	Breast Cancer Screening	104	-0.2058	<.0001	-0.2062	<.0001	-0.207	<.0001
	BPD	Diabetes Treatment	42	0.0008	0.9816	-0.0056	0.867	-0.008	0.8098
	DDI	Drug-Drug Interactions	90	-0.2007	<.0001	-0.2084	<.0001	-0.209	<.0001
	HRM	High Risk Medication	93	-0.277	<.0001	-0.2787	<.0001	-0.279	<.0001
	IET-E	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Engagement	46	0.1768	0.1574	0.1665	0.1831	0.174	0.1583
	IET-I	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Initiation	46	0.0651	0.2529	0.0645	0.2578	0.067	0.2333
	MA-C	Medication Adherence for Cholesterol (Statins)	92	-0.0023	0.8252	-0.0015	0.8887	-0.001	0.8924
	MA-D	Medication Adherence for Diabetes Medications	89	0.0031	0.8599	0.0045	0.7978	0.004	0.8118
	MA-H	Medication Adherence for Hypertension (RAS antagonists)	92	-0.0571	<.0001	-0.0564	<.0001	-0.057	<.0001
	OMW	Osteoporosis Management in Women who had a Fracture	42	-0.2911	0.0025	-0.2915	0.0025	-0.295	0.0010
	PBH	Persistence of Beta-Blocker Treatment After a Heart Attack	78	0.3482	0.0304	0.3807	0.0209	0.367	0.0233
	PCE-B	Pharmacotherapy Management of COPD Exacerbation-Bronchodilators	84	0.5191	<.0001	0.5139	<.0001	0.503	<.0001
	PCE-S	Pharmacotherapy Management of COPD Exacerbation-Systemic Corticosteroids	84	-0.138	0.0533	-0.1287	0.1054	-0.125	0.0792
	SPR	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	98	-0.1672	0.0002	-0.166	0.0002	-0.168	0.0001
	PCR	Plan All-Cause Readmissions							
		0/1, Unadjusted	27	-0.1837	0.0033	-0.1811	0.0044	-0.186	0.0014
		0/1, Adjusted	27	-0.1488	0.0158	-0.1449	0.0207	-0.149	0.0115
		Expected	27	-0.0104	<.0001	-0.0104	<.0001	-0.011	<.0001

Sample	Measure	Measure Name	Number of PBPs	Model 1 Dual status (Within)		Model 2 Dual status (Within)		Model 3 Dual Status (Deviation)	
				Estimate	P Value	Estimate	P Value	Estimate	P Value
PBPs with 20 - 80% dual enrollment	AAP	Adults' Access to Preventive/Ambulatory Health Services	50	0.1115	<.0001	0.1129	<.0001	0.113	<.0001
	AMM	Antidepressant Medication Management-Effective Continuation Phase Treatment	45	0.017	0.759	0.0291	0.6019	0.030	0.5878
	ART	Rheumatoid Arthritis Management	43	0.071	0.4497	0.0671	0.4782	0.064	0.4957
	BCS	Breast Cancer Screening	44	-0.1163	<.0001	-0.1165	<.0001	-0.118	<.0001
	BPD	Diabetes Treatment	23	-0.0051	0.8929	-0.0091	0.8103	-0.012	0.7541
	DDI	Drug-Drug Interactions	47	-0.1616	<.0001	-0.1689	<.0001	-0.172	<.0001
	HRM	High Risk Medication	48	-0.2416	<.0001	-0.2436	<.0001	-0.244	<.0001
	IET-E	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Engagement	27	0.2008	0.141	0.2031	0.1369	0.204	0.1225
	IET-I	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Initiation	27	0.0187	0.7853	0.0193	0.7787	0.020	0.7676
	MA-C	Medication Adherence for Cholesterol (Statins)	47	-0.0305	0.028	-0.0294	0.0337	-0.029	0.0297
	MA-D	Medication Adherence for Diabetes Medications	46	0.043	0.0639	0.0444	0.0565	0.044	0.0527
	MA-H	Medication Adherence for Hypertension (RAS antagonists)	47	-0.0659	<.0001	-0.0653	<.0001	-0.065	<.0001
	OMW	Osteoporosis Management in Women who had a Fracture	15	-0.3354	0.0273	-0.3333	0.0283	-0.337	0.0098
	PBH	Persistence of Beta-Blocker Treatment After a Heart Attack	42	0.2212	0.2509	0.1945	0.3214	0.160	0.4108
	PCE-B	Pharmacotherapy Management of COPD Exacerbation-Bronchodilators	44	0.5439	<.0001	0.5347	<.0001	0.521	<.0001
	PCE-S	Pharmacotherapy Management of COPD Exacerbation-Systemic Corticosteroids	44	-0.166	0.0654	-0.1522	0.0872	-0.141	0.1103
	SPR	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	42	-0.0706	0.2281	-0.0717	0.2223	-0.074	0.1995
	PCR	Plan All-Cause Readmissions							
		0/1, Unadjusted	16	-0.1649	0.0309	-0.1825	0.0201	-0.193	0.0065
		0/1, Adjusted	16	-0.1422	0.0616	-0.1594	0.041	-0.171	0.0178
		Expected	16	-0.00717	0.0134	-0.0072	0.0136	-0.007	0.0044

Notes:

Blue color indicates the effect is negative and statistically significant meaning that dual eligibles perform worse than non-dual eligibles;

Green color indicates the effect is positive and statistically significant meaning that dual eligibles perform better than non-dual eligibles.

For reverse measures (HRM, PCR, DDI), the coefficient estimates measure the effect of the variable on NOT having outcome.

Random Effect Models (2013 data)
Comparison of Member Dual Status (Within Effect) Across Three Sampling Methods

Model	Measure	Measure Name	All PBPs			PBPs with 10-90% Dual Enrollment			PBPs with 20-80% Dual Enrollment		
			Number of PBPs	Estimate	P Value	Number of PBPs	Estimate	P Value	Number of PBPs	Estimate	P Value
Model 1	AAP	Adults' Access to Preventive/Ambulatory Health Services	293	0.0717	<.0001	112	0.0595	0.0003	50	0.1115	<.0001
	AMM	Antidepressant Medication Management-Effective Continuation Phase Treatment	174	0.0184	0.6295	84	0.0125	0.7849	45	0.017	0.759
	ART	Rheumatoid Arthritis Management	171	-0.1184	0.0439	87	-0.0317	0.657	43	0.071	0.4497
	BCS	Breast Cancer Screening	272	-0.2542	<.0001	104	-0.2058	<.0001	44	-0.1163	<.0001
	BPD	Diabetes Treatment	106	-0.0123	0.6486	42	0.0008	0.9816	23	-0.0051	0.8929
	DDI	Drug-Drug Interactions	204	-0.2163	<.0001	90	-0.2007	<.0001	47	-0.1616	<.0001
	HRM	High Risk Medication	216	-0.2865	<.0001	93	-0.277	<.0001	48	-0.2416	<.0001
	IET-E	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Engagement	113	0.1287	0.2553	46	0.1768	0.1574	27	0.2008	0.141
	IET-I	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Initiation	113	0.0136	0.7935	46	0.0651	0.2529	27	0.0187	0.7853
	MA-C	Medication Adherence for Cholesterol (Statins)	203	-0.0144	0.1337	92	-0.0023	0.8252	47	-0.0305	0.028
	MA-D	Medication Adherence for Diabetes Medications	195	-0.0032	0.8408	89	0.0031	0.8599	46	0.043	0.0639
	MA-H	Medication Adherence for Hypertension (RAS antagonists)	203	-0.0752	<.0001	92	-0.0571	<.0001	47	-0.0659	<.0001
	OMW	Osteoporosis Management in Women who had a Fracture	102	-0.2684	0.0006	42	-0.2911	0.0025	15	-0.3354	0.0273
	PBH	Persistence of Beta-Blocker Treatment After a Heart Attack	162	0.2544	0.0383	78	0.3482	0.0304	42	0.2212	0.2509
	PCE-B	Pharmacotherapy Management of COPD Exacerbation-Bronchodilators	170	0.4757	<.0001	84	0.5191	<.0001	44	0.5439	<.0001
	PCE-S	Pharmacotherapy Management of COPD Exacerbation-Systemic Corticosteroids	170	-0.0911	0.1013	84	-0.138	0.0533	44	-0.166	0.0654
	SPR	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	251	-0.2168	<.0001	98	-0.1672	0.0002	42	-0.0706	0.2281
	PCR	Plan All-Cause Readmissions									
		0/1, Unadjusted	62	-0.1598	<.0001	27	-0.1837	0.0033	16	-0.1649	0.0309
		0/1, Adjusted	62	-0.079	0.0293	27	-0.1488	0.0158	16	-0.1422	0.0616
		Expected		-0.0189	<.0001		-0.0104	<.0001		-0.00717	0.0134

Model	Measure	Measure Name	All PBPs			PBPs with 10-90% Dual Enrollment			PBPs with 20-80% Dual Enrollment		
			Number of PBPs	Estimate	P Value	Number of PBPs	Estimate	P Value	Number of PBPs	Estimate	P Value
Model 2											
	AAP	Adults' Access to Preventive/Ambulatory Health Services	293	0.0706	<.0001	112	0.0606	0.0002	50	0.1129	<.0001
	AMM	Antidepressant Medication Management-Effective Continuation Phase Treatment	174	0.0753	0.0622	84	0.0297	0.5194	45	0.0291	0.6019
	ART	Rheumatoid Arthritis Management	171	-0.0631	0.3333	87	-0.0204	0.7774	43	0.0671	0.4782
	BCS	Breast Cancer Screening	272	-0.2585	<.0001	104	-0.2062	<.0001	44	-0.1165	<.0001
	BPD	Diabetes Treatment	106	-0.0408	0.1472	42	-0.0056	0.867	23	-0.0091	0.8103
	DDI	Drug-Drug Interactions	204	-0.2288	<.0001	90	-0.2084	<.0001	47	-0.1689	<.0001
	HRM	High Risk Medication	216	-0.287	<.0001	93	-0.2787	<.0001	48	-0.2436	<.0001
	IET-E	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Engagement	113	0.0722	0.541	46	0.1665	0.1831	27	0.2031	0.1369
	IET-I	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Initiation	113	-0.0008	0.9873	46	0.0645	0.2578	27	0.0193	0.7787
	MA-C	Medication Adherence for Cholesterol (Statins)	203	-0.0126	0.1924	92	-0.0015	0.8887	47	-0.0294	0.0337
	MA-D	Medication Adherence for Diabetes Medications	195	0.0045	0.7843	89	0.0045	0.7978	46	0.0444	0.0565
	MA-H	Medication Adherence for Hypertension (RAS antagonists)	203	-0.0713	<.0001	92	-0.0564	<.0001	47	-0.0653	<.0001
	OMW	Osteoporosis Management in Women who had a Fracture	102	-0.3092	0.0001	42	-0.2915	0.0025	15	-0.3333	0.0283
	PBH	Persistence of Beta-Blocker Treatment After a Heart Attack	162	0.2972	0.0437	78	0.3807	0.0209	42	0.1945	0.3214
	PCE-B	Pharmacotherapy Management of COPD Exacerbation-Bronchodilators	170	0.453	<.0001	84	0.5139	<.0001	44	0.5347	<.0001
	PCE-S	Pharmacotherapy Management of COPD Exacerbation-Systemic Corticosteroids	170	-0.0859	0.1665	84	-0.1287	0.0732	44	-0.1522	0.0872
	SPR	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	251	-0.2131	<.0001	98	-0.166	0.0002	42	-0.0717	0.2223
	PCR	Plan All-Cause Readmissions									
		0/1, Unadjusted	62	-0.2056	<.0001	27	-0.1811	0.0044	16	-0.1825	0.0201
		0/1, Adjusted	62	-0.1253	0.0109	27	-0.1449	0.0207	16	-0.1594	0.041
		Expected		-0.0189	<.0001		-0.0104	<.0001		-0.0072	0.0136

Model	Measure	Measure Name	All PBPs			PBPs with 10-90% Dual Enrollment			PBPs with 20-80% Dual Enrollment		
			Number of PBPs	Estimate	P Value	Number of PBPs	Estimate	P Value	Number of PBPs	Estimate	P Value
Model 3											
	AAP	Adults' Access to Preventive/Ambulatory Health Services	293	0.071	<.0001	112	0.061	0.0001	50	0.113	<.0001
	AMM	Antidepressant Medication Management-Effective Continuation Phase Treatment	174	0.076	0.0581	84	0.030	0.5091	45	0.030	0.5878
	ART	Rheumatoid Arthritis Management	171	-0.064	0.3294	87	-0.022	0.7592	43	0.064	0.4957
	BCS	Breast Cancer Screening	272	-0.258	<.0001	104	-0.207	<.0001	44	-0.118	<.0001
	BPD	Diabetes Treatment	106	-0.041	0.1384	42	-0.008	0.8098	23	-0.012	0.7541
	DDI	Drug-Drug Interactions	204	-0.229	<.0001	90	-0.209	<.0001	47	-0.172	<.0001
	HRM	High Risk Medication	216	-0.287	<.0001	93	-0.279	<.0001	48	-0.244	<.0001
	IET-E	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Engagement	113	0.084	0.4754	46	0.174	0.1583	27	0.204	0.1225
	IET-I	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment-Initiation	113	0.005	0.9270	46	0.067	0.2333	27	0.020	0.7676
	MA-C	Medication Adherence for Cholesterol (Statins)	203	-0.013	0.1922	92	-0.001	0.8924	47	-0.029	0.0297
	MA-D	Medication Adherence for Diabetes Medications	195	0.005	0.7793	89	0.004	0.8118	46	0.044	0.0527
	MA-H	Medication Adherence for Hypertension (RAS antagonists)	203	-0.071	<.0001	92	-0.057	<.0001	47	-0.065	<.0001
	OMW	Osteoporosis Management in Women who had a Fracture	102	-0.312	<.0001	42	-0.295	0.0010	15	-0.337	0.0098
	PBH	Persistence of Beta-Blocker Treatment After a Heart Attack	162	0.298	0.0422	78	0.367	0.0233	42	0.160	0.4108
	PCE-B	Pharmacotherapy Management of COPD Exacerbation-Bronchodilators	170	0.444	<.0001	84	0.503	<.0001	44	0.521	<.0001
	PCE-S	Pharmacotherapy Management of COPD Exacerbation-Systemic Corticosteroids	170	-0.087	0.1571	84	-0.125	0.0792	44	-0.141	0.1103
	SPR	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	251	-0.216	<.0001	98	-0.168	0.0001	42	-0.074	0.1995
	PCR	Plan All-Cause Readmissions									
		0/1, Unadjusted	62	-0.210	<.0001	27	-0.186	0.0014	16	-0.193	0.0065
		0/1, Adjusted	62	-0.129	0.0067	27	-0.149	0.0115	16	-0.171	0.0178
		Expected	62	-0.019	<.0001	27	-0.011	<.0001	16	-0.007	0.0044

Notes:

Blue color indicates the effect is negative and statistically significant meaning that dual eligibles perform worse than non-dual eligibles;

Green color indicates the effect is positive and statistically significant meaning that dual eligibles perform better than non-dual eligibles.

For reverse measures (HRM, PCR, DDI), the coefficient estimates measure the effect of the variable on NOT having outcome.